By using our site you accept the terms of our cookie policy

Investigation of Trinity Biotech plc

October 31, 2016

Image

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Trinity Biotech plc (“Trinity” or the “Company”) concerning the Company and its officers’ possible violations of federal securities laws.

Trinity acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.

The investigation concerns Trinity’s October 4, 2016 announcement that the Company was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the recommendation of the U.S. Food and Drug Administration. On news of the withdrawal, Trinity’s share price fell over 50% to close at just $6.46 per share on October 4, 2016, thereby injuring investors.

If you purchased Trinity securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Contact Us

+44 (0) 203 725 6841